Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (August 2016)
22 slides from Inspiremd's investor presentation, Aug 10, 2016
Slide 1: InspireMD, August 2016
inspirelMD NYSE MKT: NSPR August 2016
Slide 2: InspireMD
InspireMD Pioneering fully integrated embolic prevention systems and other advanced medical technology for vascular procedures NYSE MKT: NSPR inspireMD Stock Price (8/5/16): 52 Week Range: Average Volume: Shares Outstanding (8/5/16): Shares Outstanding Including Future Pref. Stock Conv. (8/5/16): Ma
Slide 3: Investment Highlights
Investment Highlights inspirelMID Focused on commercial execution of CGuard™ EPS and development of pipeline products 2016 focus on revenue growth driven by a broader EU launch of CGuard * Strategic distribution partnership with Penumbra (NYSE:PEN) * Significant growth in Italy over the last 3 quart
Slide 4: The Problem
The Problem inspireMD Embolization can lead to catastrophic health events E WALL STREET JOURI us. Stents Boost Stroke Recovery, Study Finds ; II Clots From Brain Arteries Can Help Pat 8y THOMAS M. BURTON, Usin om brain arter stroke, according Kew ; 2 icine Times Essentials searen Heat os Insice Heat
Slide 5: Embolization following Carotid Artery Stenting
Embolization following Carotid Artery Stenting inspirellID “Plaque protrusion through stent struts occurs in up to 65.5% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolizati
Slide 6: The Consequences
The Consequences inspire Range from neurological deficit to stroke to death Pre-Procedure Post-Procedure A. Pre-intervention showing 90% occlusion of the carotid B. Post-intervention showing successful opening of the artery and an MRI showing an old white matter infarction occluded carotid artery wi
Slide 7: MicroNet™
aN MicroNet™ InspirelViD Proprietary technology for preventing distal embolization and other vascular disease challenges Ultrathin PET* mesh provides meaningful clinical benefit to conventional devices + Provides revascularization benefit * MicroNet acts as “safety net” by offering greater vessel ar
Slide 8: Large Addressable Market
Large Addressable Market Expanding the MicroNet™ Platform MGuard™* ¥ $1.7B AMI Market v CE Mark Cleared ¥ Coronary AMI, SVG * MGuard isa bare metal stent scaffold CGuard™ ¥ $500M Market ¥ CE Mark Cleared ¥ FDAIDE draft protocol synopsis ¥ Carotid inspirelMD NGuard ¥ $125M Flow Diversion Market ¥ $55
Slide 9: Carotid Solution: Mesh Covered Technology
Ne Carotid Solution: Mesh Covered Technology inspireMD An emerging market opportunity CGuard™ Embolic Prevention System(EPS) Combines stent and embolic protection in a single device CE marked Self-expanding nitinol stent Global market valued at $500M* Positive CARENET data released 9/14, 1/15 and 5/
Slide 10: Positive CGuard™ Clinical Experience
Positive CGuard™ Clinical Experience inspirelID CARENET Clinical Trial + 30 Patient Safety and Efficacy clinical trial + Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") + 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to
Slide 11: Carotid Market Opportunity
Carotid Market Opportunity inspirelMD “Game Changing” Minimally Invasive Solution + Current standard of care: Surgery + Carotid Endarterectomy (CEA) * The risk of post-procedural cerebral events has been related to [conventional] carotid stents.* + Higher risks of stroke at 10 years appear to be att
Slide 12: Strategic Distribution Partnership
aN: Strategic Distribution Partnership Imspure/VID Broad European commercialization support from a growing neurovascular leader Penumbra re) + Distribution agreement with Penumbra + 18 European markets with opportunity to expand * Comprehensive neurovascular product portfolio * CGuard is a synergist
Slide 13: CGuard Distribution (EU)
CGuard Distribution (EU) inspireMD Penumbra (Direct) 18 Countries InspireMD or O18 Distributor IND NOTE (Penumbra, CK (Crossmed/Roste) 12 (408) I spire O/Dstbvtr) 13
Slide 14: CGuard™ Country Case Study
aN CGuard™ Country Case Study inspirelID Italy — A leading indicator of CGuard Growth + CGuard covered by 2 distributors + Initial success drove 29 Italian carotid interventionalists to initiate the IRON-Guard* registry last year Italy CGuard Revenue 160 140 120 100 80 60 40 20 i o @ a3 aa ai1s a1 1
Slide 15: Robust Pipeline
oN Robust Pipeline inspirelViD Expanding Indications with MicroNet™ ” Commercial + CE Mark Cleared + 12-month MASTER |, I MGuard™ Coronary EPS Commercial * CE Mark Cleared + CARENET Trial omni RGuard™ CGuard™ + PARADIGM all-comer trials Renal* Carotid + FDAIDE draft protocol synopsis + Penumbra Stra
Slide 16: Neurovascular Aneurysms
Neurovascular Aneurysms inspirelMD Flow Diversion Objective * Seal the aneurysm and prevent rupture Current device therapies * Coils to pack the aneurysm + Flow diverters * Highly flexible, dense metal “tube” + Placed in main artery to seal off aneurysm and cause aneurysm thrombosis * Precise delive
Slide 17: Neurovascular Market Opportunity
Neurovascular Market Opportunity inspirelMD Innovation leads growth Flow Diversion For Unruptured Brain Aneurysms Next Generation Technology + Aneurysm Therapy (all types): $550M* + Flow diverters are estimated to be 25% of the aneurysm market + Neurovascular products: estimated 15% CAGR from 2010-2
Slide 18: InspireMD Flow Diverter Advantage
oe InspireMD Flow Diverter Advantage inspireMD + Low profile, flexible, open cell scaffold = Easy to delivery + Low metal ratio = Potential for reduced anti-thrombosis medication + Re-accessible through MicroNet™ = Allows for further treatment, if needed which is impossible with current flow diverte
Slide 19: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD Rest of World (ROW) 16 0 13 Continue to strengthen and broaden patent protection globally. Progress over the last year imparts important rights on existing products and technologies and will enable future pipeline products. 419
Slide 20: Leadership
aN Leadership InspirelViD Significant Track Records of Success EXECUTIVE TEAM BOARD OF DIRECTORS Dr. James Barry, President and CEO Dr. Sol Barer, Chairman * Boston Scientific ; * Former Chairman and CEO, Celgene 2 (netuIcaTEe Ne STS AES Isaac Blech, Vice Chairman Craig Shore, CFO * Private financie
Slide 21: Investment Highlights
Investment Highlights inspirelID Focused on commercial execution of CGuard™ EPS and development of pipeline products 2016 focus on revenue growth driven by a broader EU launch of CGuard * Strategic distribution partnership with Penumbra (NYSE:PEN) * Significant growth in Italy over the last 3 quarte
Slide 22: InspireMD
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com